US4278684A - Non-toxic anthelminthic pour-on composition - Google Patents

Non-toxic anthelminthic pour-on composition Download PDF

Info

Publication number
US4278684A
US4278684A US06/160,248 US16024880A US4278684A US 4278684 A US4278684 A US 4278684A US 16024880 A US16024880 A US 16024880A US 4278684 A US4278684 A US 4278684A
Authority
US
United States
Prior art keywords
pour
composition according
amount
varying
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/160,248
Inventor
Guido J. L. Van der Veken
Jozef C. J. Dockx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to US06/160,248 priority Critical patent/US4278684A/en
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DOCKX JOZEF C. J., VAN DER VEKEN GUIDO J. L.
Priority to CA000377575A priority patent/CA1157770A/en
Priority to NZ197293A priority patent/NZ197293A/en
Priority to AU71322/81A priority patent/AU545531B2/en
Priority to EP81302684A priority patent/EP0042290B1/en
Priority to ZA814059A priority patent/ZA814059B/en
Priority to DE8181302684T priority patent/DE3172322D1/en
Priority to IE1335/81A priority patent/IE51329B1/en
Priority to AT81302684T priority patent/ATE15597T1/en
Publication of US4278684A publication Critical patent/US4278684A/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017Non-human animal skin, e.g. pour-on, spot-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles

Definitions

  • the method of systemically administering drugs by pouring or spraying a composition, comprising the desired drug, onto any part of the skin is generally known in veterinary medicine as the pour-on method.
  • Drugs, administered following this method are absorbed by the skin and, after they have penetrated through the skin, they are transmitted systemically within the animal. [see, for example, W. M. Rogoff and P. H. Kohler, J. Econ. Ent., 53, 814-817 (1960) and B. Idson, J. Pharm., Sci., 64, 901-924 (1975)].
  • the drug is preferably applied in admixture with an appropriate carrier, which may be any liquid, taking up an adequate amount of the anthelminthic and permitting an adequate resorption of the drug through the skin without damaging the tissues.
  • an appropriate carrier may also consist of a mixture of vehicles, the resulting composition being a cream, a suspension or a solution.
  • the pour-on method offers distinct advantages. For example, there is no need to hold the animal, sterile precautions are not necessary and especially trained personal is not required.
  • the pour-on method has the advantage that each animal receives an exactly defined amount of the desired drug.
  • Tetramisole being chemically designated as 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the laevo isomer thereof, levamisole, have been described in U.S. Pat. Nos. 3,274,209, respectively 3,463,786.
  • the compounds are powerful anthelminthic agents.
  • Structurally, tetramisole is represented by the formula ##
  • Anthelminthic pour-on compositions which contain tetramisole, levamisole or an acid-addition salt thereof, have been described in U.S. Pat. Nos. 4,070,476 and 3,980,791. Said compositions have the disadvantage that the carriers, which are the most effective for helping the penetration of the anthelminthic through the skin, are at the same time the most aggressive to the treated skin, resulting in, for example, subcutaneous bleedings, necrosis, hair and skin diseases and, at worst, open wounds. [severe skin irritations, caused by pour-on compositions, are described, e.g., in Veterinar Medizinische sensoryen 1978 (1), 109-112].
  • the present invention describes new pour-on compositions for combating helminthic infestations in a non-human animal.
  • the subject compositions are less aggressive and, due to their enhanced skin penetration, they are yielding higher plasma levels.
  • This invention relates to pour-on compositions for combating helminthic infestations in a non-human animal, which comprise:
  • a an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
  • one or more optionally substituted aliphatic carboxylic acids having each a pKa-value comprised between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3;
  • the pKa-value has the meaning of -logKa, wherein Ka is the dissociation constant of the most acidic function of the molecule at 25° C. in aqueous medium;
  • the term "lower alkyl” is meant to include straight and branched hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl and the like; and "alkylene” comprises straight and branched alkylene chains.
  • Suitable optionally substituted aliphatic carboxylic acids are, for example, acetic acid, propionic acid, citric acid, lactic acid and the like. It is unexpectedly observed that in the subject compositions the said carboxylic acids act as specific skin penetration promotors.
  • compositions according to the present invention are those wherein the molar ratio of the total amount of the aliphatic carboxylic acids and the total amount of the anthelminthics varies between 0.05 and 1, said carboxylic acids having, more preferably, a pKa-value comprised between 4 and 5.5.
  • Particularly preferred compositions are those wherein the aliphatic carboxylic acid is acetic acid.
  • Diesters of formula (II) wherein X is a lower alkylene radical having from 3 to 10 C-atoms are especially preferred and compositions containing 25 to 60% of such diesters are more especially preferred.
  • Particularly preferred diesters of formula (II) are the di(lower alkyl) esters of adipic acid and the most preferred diesters of formula (II) are those wherein both lower alkyl radicals have 3 carbon atoms.
  • levamisole is employed as the anthelminthically active agent, and, in the most preferred embodiment the composition contains from 5 to 20 g. levamisole per 100 ml. of the resulting compositions.
  • compositions may also contain additives which may facilitate the administration to the skin of the animal and/or which may be helpful for preparing the desired compositions.
  • the compositions preferably comprise also from 10 to 60% of an aliphatic hydrocarbon mixture.
  • Said aliphatic hydrocarbons which reduce the surface tension of the compositions, prevent at the same time an excessive adhesion of the applied compositions to the hair and facilitate their spreading over the skin, resulting in an enhanced resorption of the anthelminthic by the skin.
  • Useful hydrocarbon mixtures have, preferably, a boiling range comprised between 150° C. and 250° C.
  • Particularly preferred hydrocarbon mixtures have a boiling range comprised between 170° C. and 230° C.
  • dipolar aprotic solvents which act as a specific penetration promotors and skin protectants, may be advantageous.
  • Suitable dipolar aprotic solvents are e.g., N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, N-methyl-2-pyrrolidone and the like.
  • Preferred compositions contain from 1 to 30% of a suitable hydrating agent. In the particularly preferred compositions said hydrating agent is N-methyl-2-pyrrolidone. The most preferred compositions contain from 5 to 15% of N-methyl-2-pyrrolidone.
  • compositions which are homogeneous In order to prepare compositions which are homogeneous, even at relatively low temperatures, it may be appropriate to add a co-solvent such as, for example, alcohols, e.g., 2-propanol and the like.
  • a co-solvent such as, for example, alcohols, e.g., 2-propanol and the like.
  • Preferred compositions contain from 0 to 10% of a co-solvent and particularly preferred compositions contain from 0 to 5% of a co-solvent.
  • the most preferred co-solvent is 2-propanol.
  • compositions may also contain other additives such as, for example, substances whose taste deters animals from licking the applied compositions off the animals treated, pigments making it possible to recognize the treated animals and the like.
  • compositions are especially characterized by their effectiveness and by their low ratio of irritation.
  • the effectiveness of the concerned anthelminthic pour-on compositions can be demonstrated by the amount of levamisole or tetramisole present in the blood plasma of the animal after treatment of said animal with one of the hereinabove described compositions.
  • Venous blood samples are taken on a coagulating agent, e.g., heparine and the like, and, subsequently, they are mixed and centrifugated at 3000 rpm for 5 minutes, thus yielding a supernatant plasma.
  • a coagulating agent e.g., heparine and the like
  • An aqueous solution consisting of 2 ml. of the above described supernatant plasma, 100 ⁇ l. of a 10 ng/ml. solution of an internal standard, preferably ( ⁇ )-2,3,5,6-tetrahydro-6-(4-methylphenyl)imidazo[2,1-b]thiazole hydrochloride, and 0.5 ml. of sodium hydroxide 10 N is extracted with 4 ml. of a hexane/ether (1/1) mixture. The organic layer is separated and extracted with 2 ml. of a 0.1 N sulfuric acid solution.
  • an internal standard preferably ( ⁇ )-2,3,5,6-tetrahydro-6-(4-methylphenyl)imidazo[2,1-b]thiazole hydrochloride
  • sodium hydroxide 10 N is extracted with 4 ml. of a hexane/ether (1/1) mixture.
  • the organic layer is separated and extracted with 2 ml. of a 0.1 N sulfuric acid solution.
  • the aqueous layer is separated, washed with a hexane/ether mixture, alkalized with ammonia to pH 9 and extracted with trichloromethane.
  • the trichloromethane layer is separated and the solvent is evaporated at 40° C. under a gentle stream of nitrogen.
  • the amount of tetramisole and/or levamisole is determined by separating the components which are present in the hereinabove described sample following art-known gas chromatographic techniques and, subsequently, by comparing the peak area of levamisole and/or tetramisole with the peak area of the internal standard.
  • the levamisole and/or tetramisole plasma levels can be determined by the formula: ##EQU1## wherein F is the response factor, which may be determined by the formula: ##EQU2## wherein AI, respectively AR, is the peak area of the internal standard, respectively of the reference compound, and wherein CR and CI are the concentration of the reference compound, respectively the internal standard.
  • Table 1 shows the concentrations of levamisole in the blood-plasma of cattle, which have received levamisole by pouring on the back of the animal a composition
  • a composition comprising:
  • Shellsol T is an aliphatic hydrocarbon fraction having a boiling range comprised between 170° C. and 230° C.
  • Column 1 shows the average concentration of levamisole in the plasma of 12 cattle 0.5, 1, 2 and 4 hours after administration of 10 mg per kg of body weight and column 2 shows the average concentrations after administering 4 mg per kg of body weight to 4 cattle.
  • Table 2 shows the average concentrations of levamisole in the bloodplasma of 3 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
  • Table 3 shows the average concentrations of levamisole in the blood-plasma of 2 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
  • Table 4 shows the concentration of levamisole in the bloodplasma of a sheep after treatment with 20 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
  • composition comprising:
  • compositions can be prepared in a conventional manner, e.g., by adding the desired amounts of levamisole and/or tetramisole to a well-stirred mixture consisting of suitable amounts of the optionally substituted aliphatic carboxylic acids, the di(lower alkyl) carboxylic acid esters of formula (II), the co-solvent and the hydrating agents, and, subsequently, diluting the thus obtained mixture with an appropriate aliphatic hydrocarbon fraction.
  • compositions are useful for combating helminthic infestations in all non-human animals, said compositions are especially preferred for the treatment of cattle and sheep.
  • composition 1 composition 1:
  • Composition 2 is a composition of Composition 2:
  • composition 3 is a mixture of composition 3:
  • composition 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to non-aggressive pour-on compositions for combating helminthic infestations in a non-human animal, said compositions comprising an anthelminthic amount of tetramisole and/or levamisole, a carboxylic acid and a di(lower alkyl) ester of a dicarboxylic acid.

Description

DESCRIPTION OF THE INVENTION
The method of systemically administering drugs by pouring or spraying a composition, comprising the desired drug, onto any part of the skin is generally known in veterinary medicine as the pour-on method. Drugs, administered following this method, are absorbed by the skin and, after they have penetrated through the skin, they are transmitted systemically within the animal. [see, for example, W. M. Rogoff and P. H. Kohler, J. Econ. Ent., 53, 814-817 (1960) and B. Idson, J. Pharm., Sci., 64, 901-924 (1975)]. In order to facilitate the penetration through the skin the drug is preferably applied in admixture with an appropriate carrier, which may be any liquid, taking up an adequate amount of the anthelminthic and permitting an adequate resorption of the drug through the skin without damaging the tissues. Said carrier may also consist of a mixture of vehicles, the resulting composition being a cream, a suspension or a solution.
In comparison with the parenteral administration methods the pour-on method offers distinct advantages. For example, there is no need to hold the animal, sterile precautions are not necessary and especially trained personal is not required.
In comparison with the oral administration methods, the pour-on method has the advantage that each animal receives an exactly defined amount of the desired drug.
Tetramisole, being chemically designated as 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the laevo isomer thereof, levamisole, have been described in U.S. Pat. Nos. 3,274,209, respectively 3,463,786. The compounds are powerful anthelminthic agents. Structurally, tetramisole is represented by the formula ##STR1##
Anthelminthic pour-on compositions which contain tetramisole, levamisole or an acid-addition salt thereof, have been described in U.S. Pat. Nos. 4,070,476 and 3,980,791. Said compositions have the disadvantage that the carriers, which are the most effective for helping the penetration of the anthelminthic through the skin, are at the same time the most aggressive to the treated skin, resulting in, for example, subcutaneous bleedings, necrosis, hair and skin diseases and, at worst, open wounds. [severe skin irritations, caused by pour-on compositions, are described, e.g., in Veterinar Medizinische Nachrichten 1978 (1), 109-112].
The present invention describes new pour-on compositions for combating helminthic infestations in a non-human animal. In comparison with the art-known compositions the subject compositions are less aggressive and, due to their enhanced skin penetration, they are yielding higher plasma levels.
This invention relates to pour-on compositions for combating helminthic infestations in a non-human animal, which comprise:
a. an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
b. one or more optionally substituted aliphatic carboxylic acids, having each a pKa-value comprised between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3; and
c. an amount, varying from 10 to 70% by volume, of at least one di(lower alkyl) dicarboxylic acid ester of the formula ##STR2## wherein X represents a direct bond or an alkylene radical having from 1 to 12 carbon atoms.
As used in the foregoing and in the following definitions all percentages refer to volumes; the pKa-value has the meaning of -logKa, wherein Ka is the dissociation constant of the most acidic function of the molecule at 25° C. in aqueous medium; the term "lower alkyl" is meant to include straight and branched hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl and the like; and "alkylene" comprises straight and branched alkylene chains.
Suitable optionally substituted aliphatic carboxylic acids are, for example, acetic acid, propionic acid, citric acid, lactic acid and the like. It is unexpectedly observed that in the subject compositions the said carboxylic acids act as specific skin penetration promotors.
Preferred compositions according to the present invention are those wherein the molar ratio of the total amount of the aliphatic carboxylic acids and the total amount of the anthelminthics varies between 0.05 and 1, said carboxylic acids having, more preferably, a pKa-value comprised between 4 and 5.5. Particularly preferred compositions are those wherein the aliphatic carboxylic acid is acetic acid.
Diesters of formula (II) wherein X is a lower alkylene radical having from 3 to 10 C-atoms are especially preferred and compositions containing 25 to 60% of such diesters are more especially preferred. Particularly preferred diesters of formula (II) are the di(lower alkyl) esters of adipic acid and the most preferred diesters of formula (II) are those wherein both lower alkyl radicals have 3 carbon atoms.
Since the anthelminthic activity of tetramisole is exerted essentially by the laevo isomer, in a preferred embodiment levamisole is employed as the anthelminthically active agent, and, in the most preferred embodiment the composition contains from 5 to 20 g. levamisole per 100 ml. of the resulting compositions.
Besides one or more anthelminthic agents, one or more diesters of formula (II) and one or more optionally substituted aliphatic carboxylic acids the compositions may also contain additives which may facilitate the administration to the skin of the animal and/or which may be helpful for preparing the desired compositions.
In order to reduce their viscosity, the compositions preferably comprise also from 10 to 60% of an aliphatic hydrocarbon mixture. Said aliphatic hydrocarbons, which reduce the surface tension of the compositions, prevent at the same time an excessive adhesion of the applied compositions to the hair and facilitate their spreading over the skin, resulting in an enhanced resorption of the anthelminthic by the skin. Useful hydrocarbon mixtures have, preferably, a boiling range comprised between 150° C. and 250° C. Particularly preferred hydrocarbon mixtures have a boiling range comprised between 170° C. and 230° C.
The presence of dipolar aprotic solvents, which act as a specific penetration promotors and skin protectants, may be advantageous. Suitable dipolar aprotic solvents are e.g., N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, N-methyl-2-pyrrolidone and the like. Preferred compositions contain from 1 to 30% of a suitable hydrating agent. In the particularly preferred compositions said hydrating agent is N-methyl-2-pyrrolidone. The most preferred compositions contain from 5 to 15% of N-methyl-2-pyrrolidone.
In order to prepare compositions which are homogeneous, even at relatively low temperatures, it may be appropriate to add a co-solvent such as, for example, alcohols, e.g., 2-propanol and the like. Preferred compositions contain from 0 to 10% of a co-solvent and particularly preferred compositions contain from 0 to 5% of a co-solvent. The most preferred co-solvent is 2-propanol.
The compositions may also contain other additives such as, for example, substances whose taste deters animals from licking the applied compositions off the animals treated, pigments making it possible to recognize the treated animals and the like.
The above described compositions are especially characterized by their effectiveness and by their low ratio of irritation.
The effectiveness of the concerned anthelminthic pour-on compositions can be demonstrated by the amount of levamisole or tetramisole present in the blood plasma of the animal after treatment of said animal with one of the hereinabove described compositions.
THE EXPERIMENTAL DETERMINATION OF LEVAMISOLE AND/OR TETRAMISOLE IN BLOOD PLASMA
1. Sample preparation:
Venous blood samples are taken on a coagulating agent, e.g., heparine and the like, and, subsequently, they are mixed and centrifugated at 3000 rpm for 5 minutes, thus yielding a supernatant plasma.
2. Extraction procedure:
An aqueous solution, consisting of 2 ml. of the above described supernatant plasma, 100 μl. of a 10 ng/ml. solution of an internal standard, preferably (±)-2,3,5,6-tetrahydro-6-(4-methylphenyl)imidazo[2,1-b]thiazole hydrochloride, and 0.5 ml. of sodium hydroxide 10 N is extracted with 4 ml. of a hexane/ether (1/1) mixture. The organic layer is separated and extracted with 2 ml. of a 0.1 N sulfuric acid solution. Subsequently the aqueous layer is separated, washed with a hexane/ether mixture, alkalized with ammonia to pH 9 and extracted with trichloromethane. The trichloromethane layer is separated and the solvent is evaporated at 40° C. under a gentle stream of nitrogen. To the dry extraction sample there are added 50 μl. of pure methanol, thus yielding a sample which is suitable for gas chromatographic analysis.
3. Determination and calculations:
The amount of tetramisole and/or levamisole is determined by separating the components which are present in the hereinabove described sample following art-known gas chromatographic techniques and, subsequently, by comparing the peak area of levamisole and/or tetramisole with the peak area of the internal standard.
The levamisole and/or tetramisole plasma levels can be determined by the formule: ##EQU1## wherein F is the response factor, which may be determined by the formule: ##EQU2## wherein AI, respectively AR, is the peak area of the internal standard, respectively of the reference compound, and wherein CR and CI are the concentration of the reference compound, respectively the internal standard.
The plasma-levels represented in tables 1, 2, 3 and 4 are intended to illustrate and not to limit the scope of the present invention.
Table 1 shows the concentrations of levamisole in the blood-plasma of cattle, which have received levamisole by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid; and
Shellsol T ad 100 ml,
wherein Shellsol T is an aliphatic hydrocarbon fraction having a boiling range comprised between 170° C. and 230° C.
Column 1 shows the average concentration of levamisole in the plasma of 12 cattle 0.5, 1, 2 and 4 hours after administration of 10 mg per kg of body weight and column 2 shows the average concentrations after administering 4 mg per kg of body weight to 4 cattle.
              TABLE 1                                                     
______________________________________                                    
       μg. levamisole/ml blood plasma                                  
time after                                                                
         administered    administered                                     
treatment                                                                 
         dose = 10 mg/kg body                                             
                         dose = 4 mg/kg body                              
in hours weight          weight                                           
______________________________________                                    
0.5      0.73            0.29                                             
1        1.44            0.48                                             
2        1.14            0.40                                             
4        0.48            0.19                                             
______________________________________                                    
Table 2 shows the average concentrations of levamisole in the bloodplasma of 3 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
0.5 ml. acetic acid (column a) or
3 ml. acetic acid (column b); and
Shellsol T ad 100 ml.
              TABLE 2                                                     
______________________________________                                    
            μg. levamisole/ml blood plasma                             
time after  administered dose = 10 mg/kg body weight                      
treatment in hours                                                        
            0.5% acetic acid                                              
                          3% acetic acid                                  
______________________________________                                    
0.5         0.97          0.74                                            
1           1.83          1.76                                            
2           0.97          1.17                                            
4           0.58          0.50                                            
______________________________________                                    
Table 3 shows the average concentrations of levamisole in the blood-plasma of 2 cattle after treatment with 10 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. dibutyl sebacic acid ester;
5 ml. 2-propanol;
1 ml.acetic acid; and
Shellsol T ad 100 ml.
              TABLE 3                                                     
______________________________________                                    
time after μg. levamisole/ml blood plasma                              
treatment in hours                                                        
           administered dose = 10 mg/kg body weight                       
______________________________________                                    
0.5        0.72                                                           
1          1.17                                                           
2          0.95                                                           
4          0.27                                                           
______________________________________                                    
Table 4 shows the concentration of levamisole in the bloodplasma of a sheep after treatment with 20 mg of levamisole per kg of body weight by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid; and
Shellsol T ad 100 ml., (column a).
and by pouring on the back of the animal a composition comprising:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. dibutyl sebacic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid; and
Shellsol T ad 100 ml. (column b).
              TABLE 4                                                     
______________________________________                                    
time after μg. levamisole/ml blood plasma                              
treatment  administered dose = 20 mg/kg body weight                       
in hours   column a       column b                                        
______________________________________                                    
0.5        0.35           0.29                                            
1          0.40           0.30                                            
2          0.79           0.39                                            
4          0.48           1.02                                            
______________________________________                                    
The hereinabove described compositions can be prepared in a conventional manner, e.g., by adding the desired amounts of levamisole and/or tetramisole to a well-stirred mixture consisting of suitable amounts of the optionally substituted aliphatic carboxylic acids, the di(lower alkyl) carboxylic acid esters of formula (II), the co-solvent and the hydrating agents, and, subsequently, diluting the thus obtained mixture with an appropriate aliphatic hydrocarbon fraction.
Although the hereinabove described compositions are useful for combating helminthic infestations in all non-human animals, said compositions are especially preferred for the treatment of cattle and sheep.
The following examples are intended to illustrate and not to limit the scope of the present invention.
EXAMPLE 1
Over a period of 20 minutes, 10 grams of levamisole are added to a well-stirred mixture, consisting of
10 ml. anhydric N-methyl-2-pyrrolidone;
35 ml. diisopropyl adipate;
5 ml. 2-propanol; and
1 ml. acetic acid.
After completion, the whole is diluted to 100 ml. with Shellsol T.
EXAMPLE 2
Following the procedure described in Example 1 the following compositions are prepared:
composition 1:
10 g. levamisole;
10 ml. N-methyl-2-pyrrolidone;
35 ml. di(2-propyl) adipic acid ester;
5 ml. 2-propanol;
1 ml. acetic acid;
Shellsol T ad 100 ml.
Composition 2:
10 g. levamisole;
10 ml N-methyl-2-pyrrolidone;
35 ml di(2-propyl) adipic acid ester;
5 ml 2-propanol;
0.5 ml acetic acid;
Shellsol T ad 100 ml.
composition 3:
10 g. levamisole;
10 ml N-methyl-2-pyrrolidone;
35 ml di(2-propyl) adipic acid ester;
5 ml 2-propanol;
3 ml acetic acid;
Shellsol T ad 100 ml.
composition 4:
10 g. levamisole;
10 ml N-methyl-2-pyrrolidone;
35 ml dibutyl sebacic acid ester;
5 ml 2-propanol;
1 ml acetic acid;
Shellsol T ad 100 ml.

Claims (19)

What is claimed is:
1. A pour-on composition for combating helminthic infestations in a non-human animal, comprising:
a. an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
b. one or more aliphatic carboxylic acids, having each a pKa-value between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3; and
c. an amount, varying from 10 to 70% by volume, of at least one di(lower alkyl) dicarboxylic acid ester of the formula ##STR3## wherein X represents a direct bond or an alkylene radical having from 1 to 12 carbon atoms.
2. A pour-on composition according to claim 1, containing additionally from 1 to 30% of a dipolar aprotic solvent.
3. A pour-on composition according to claim 2, containing additionally from 10 to 60% of an aliphatic hydrocarbon fraction having a boiling range between 150° C. and 250° C.
4. A pour-on composition according to claim 3, wherein the aliphatic hydrocarbon fraction has a boiling range between 170° C. and 230° C.
5. A pour-on composition according to claim 4, wherein the dipolar aprotic solvent is N-methyl-2-pyrrolidone.
6. A pour-on composition for combating helminthic infestations in a non-human animal comprising:
a. an anthelminthically effective amount of dl-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and/or the laevo isomer thereof;
b. one or more aliphatic carboxylic acids, having each a pKa-value comprised between 3 and 6, the molar ratio of the total amount of said carboxylic acids to the total amount of the anthelminthics varying between 0.01 and 3;
c. an amount, varying from 10 to 70% by volume, of the at least one di(lower alkyl) dicarboxylic acid ester of the formula ##STR4## wherein X represents a direct bond or an alkylene radical having from 1 to 12 carbon atoms;
d. an amount, varying from 5 to 15% of N-methyl-2-pyrrolidone; and
e. an amount, varying from 10 to 60% of an aliphatic hydrocarbon fraction, having a boiling range between 170° C. and 230° C.
7. A pour-on composition according to claim 6, wherein X in the di(lower alkyl) dicarboxylic acid ester of formula (II) represents an alkylene radical having from 3 to 10 carbon atoms.
8. A pour-on composition according to claim 7, wherein the amount of di(lower alkyl) dicarboxylic acid ester of formula (II) varies between 25 and 60%.
9. A pour-on composition according to claim 8, wherein the di(lower alkyl) dicarboxylic acid ester of formula (II) is a di(lower alkyl) adipic acid ester.
10. A pour-on composition according to claim 9, wherein both lower alkyl radicals within the di(lower alkyl)adipic acid ester have 3 carbon atoms.
11. A pour-on composition according to claim 10, comprising additionally from 0 to 15% of a co-solvent.
12. A pour-on composition according to claim 10, comprising additionally from 0 to 5% of a co-solvent.
13. A pour-on composition according to claim 12, wherein the co-solvent is an alcohol.
14. A pour-on composition according to claim 13, wherein the co-solvent is 2-propanol.
15. A pour-on composition according to claim 14, wherein the ratio of the total amount of aliphatic carboxylic acids to the total amount of the anthelminthics varies between 0.05 and 1.
16. A pour-on composition according to claim 15, wherein the aliphatic carboxylic acids have pKa-values between 4 and 5.5.
17. A pour-on composition according to claim 16, wherein the aliphatic carboxylic acid is acetic acid.
18. A pour-on composition according to claim 17, wherein the anthelminthic is l-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole.
19. A pour-on composition for combating helminthic infestations in a non-human animal comprising:
a. from 5 to 20 g. l-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole per 100 ml of the resulting composition;
b. acetic acid, the molar ratio of the amount of acetic acid to the amount of l-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole varying between 0.05 and 1;
c. an amount, varying from 25 to 60% by volume, of di(1-propyl)adipic acid ester and/or di(2-propyl)adipic acid ester;
d. an amount, varying from 5 to 15%, of N-methyl-2-pyrrolidone;
e. an amount, varying from 10 to 60%, of an aliphatic hydrocarbon fraction, having a boiling range between 170° C. and 230° C.; and
f. an amount, varying from 0 to 5% of 2-propanol.
US06/160,248 1980-06-17 1980-06-17 Non-toxic anthelminthic pour-on composition Expired - Lifetime US4278684A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US06/160,248 US4278684A (en) 1980-06-17 1980-06-17 Non-toxic anthelminthic pour-on composition
CA000377575A CA1157770A (en) 1980-06-17 1981-05-14 Non-aggressive anthelminthic pour-on composition
NZ197293A NZ197293A (en) 1980-06-17 1981-06-03 Pour-on anthelmintic compositions containing tetramisole and/or levamisole
AU71322/81A AU545531B2 (en) 1980-06-17 1981-06-04 A non-toxic anthelmintic pour-on composition
EP81302684A EP0042290B1 (en) 1980-06-17 1981-06-16 A non-toxic anthelminthic pour-on composition
ZA814059A ZA814059B (en) 1980-06-17 1981-06-16 A non-toxic anthelminthic pour-on composition
DE8181302684T DE3172322D1 (en) 1980-06-17 1981-06-16 A non-toxic anthelminthic pour-on composition
IE1335/81A IE51329B1 (en) 1980-06-17 1981-06-16 A non-toxic anthelminthic pour-on composition
AT81302684T ATE15597T1 (en) 1980-06-17 1981-06-16 NON-TOXIC ANTHELMINTHIC COMPOSITION FOR TOPICAL USE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/160,248 US4278684A (en) 1980-06-17 1980-06-17 Non-toxic anthelminthic pour-on composition

Publications (1)

Publication Number Publication Date
US4278684A true US4278684A (en) 1981-07-14

Family

ID=22576132

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/160,248 Expired - Lifetime US4278684A (en) 1980-06-17 1980-06-17 Non-toxic anthelminthic pour-on composition

Country Status (9)

Country Link
US (1) US4278684A (en)
EP (1) EP0042290B1 (en)
AT (1) ATE15597T1 (en)
AU (1) AU545531B2 (en)
CA (1) CA1157770A (en)
DE (1) DE3172322D1 (en)
IE (1) IE51329B1 (en)
NZ (1) NZ197293A (en)
ZA (1) ZA814059B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2517205A1 (en) * 1981-11-27 1983-06-03 Ici Australia Ltd TETRAMISOLE COMPOSITION FOR TOPICAL APPLICATION TO ANIMALS
FR2517207A1 (en) * 1981-11-27 1983-06-03 Ici Australia Ltd TOPICAL PARASITICIDE COMPOSITIONS BASED ON LEVAMISOLE AND CYHALOTHRIN
WO2000074489A1 (en) * 1999-06-04 2000-12-14 Nufarm Limited Stable biocidal compositions
US8512770B2 (en) 2010-08-04 2013-08-20 Dominion Resources Unlimited, Llc Skin penetration composition

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1611383A (en) * 1982-07-02 1984-01-05 Robert Young & Company Limited Pesticidal formulation with cypermethrin
AU2314184A (en) * 1983-01-10 1984-07-12 Robert Young & Company Limited Endoparasiticidal composition containing levamisole
GB8327761D0 (en) * 1983-10-17 1983-11-16 Janssen Pharmaceutica Nv Parasiticidal formulations
JPH0747535B2 (en) * 1985-11-26 1995-05-24 日東電工株式会社 Anti-inflammatory analgesic patch
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
AU2002314847A1 (en) 2001-05-31 2002-12-09 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617653B1 (en) * 1967-09-08 1970-06-18 Meiji Seika Kaisha Indomethacin preparation for external use
IE38848B1 (en) * 1973-02-23 1978-06-07 Fisons Ltd Anthelmintic method and composition
NL180633C (en) * 1973-06-22 1900-01-01 Bayer Ag PROCESS FOR PREPARING AN ANTHELMINTIC EFFECTIVE VETERINARY Pour-on Preparation.
US4018932A (en) * 1975-11-03 1977-04-19 American Cyanamid Company Anthelmintic pour-on formulations for topical use on domestic and farm animals
DE2614841A1 (en) * 1976-04-06 1977-10-20 Bayer Ag NEW POUR-ON FORMULATIONS FROM ANTHELMINTIKA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Andrews et al., Chem. Abst. vol. 88, (1978), p. 65976j. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2517205A1 (en) * 1981-11-27 1983-06-03 Ici Australia Ltd TETRAMISOLE COMPOSITION FOR TOPICAL APPLICATION TO ANIMALS
FR2517207A1 (en) * 1981-11-27 1983-06-03 Ici Australia Ltd TOPICAL PARASITICIDE COMPOSITIONS BASED ON LEVAMISOLE AND CYHALOTHRIN
DE3244166A1 (en) * 1981-11-27 1983-06-09 ICI Australia Ltd., 3001 Melbourne, Victoria PUSH-ON COMPOSITION FOR COMBATING ECTO AND ENDOPARASITES
WO2000074489A1 (en) * 1999-06-04 2000-12-14 Nufarm Limited Stable biocidal compositions
US8512770B2 (en) 2010-08-04 2013-08-20 Dominion Resources Unlimited, Llc Skin penetration composition

Also Published As

Publication number Publication date
AU7132281A (en) 1981-12-24
AU545531B2 (en) 1985-07-18
CA1157770A (en) 1983-11-29
ZA814059B (en) 1983-01-26
ATE15597T1 (en) 1985-10-15
EP0042290A3 (en) 1982-09-22
EP0042290A2 (en) 1981-12-23
DE3172322D1 (en) 1985-10-24
IE811335L (en) 1981-12-17
NZ197293A (en) 1983-05-31
EP0042290B1 (en) 1985-09-18
IE51329B1 (en) 1986-12-10

Similar Documents

Publication Publication Date Title
CA2090422C (en) Pharmaceutical composition of florfenicol
EP0098743B1 (en) Phenyl alpha-acyloxyacetamide derivates and their therapeutic use
US4278684A (en) Non-toxic anthelminthic pour-on composition
CA1161362A (en) Pharmaceutical compositions containing a corticosteroid substance
US4100297A (en) Novel anti-acarid methods
SK17452000A3 (en) COMPOSITIONS COMPRISING ORGANIC MONO- OR DINITRATE FOR TREATINGì (54) IMPOTENCE
US4039664A (en) Topical griseofulvin composition and method
EP0137627A2 (en) Pour-on formulation for the control of parasites
KR100529660B1 (en) Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases
US4439439A (en) Non-irritating tetramisole- or levamisole pour-on conpositions
EP0061208A1 (en) Insecticidal control of ectoparasites
EP0294914A2 (en) Nedocromil for the treatment of dermatological disorders
US4395407A (en) Parasiticidal pour-on compositions
JP2002504914A (en) Diclofenac solution prescribed for topical administration
SU1697670A1 (en) Composition for control of ectoparasites of diseased (psoroptosis, sarcoptosis) farm animals and poultry
CA1252039A (en) Aqueous non-aggressive anthelmintic pour-on formulations
JPS63238018A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN DER VEKEN GUIDO J. L.;DOCKX JOZEF C. J.;REEL/FRAME:003792/0048

Effective date: 19800617

STCF Information on status: patent grant

Free format text: PATENTED CASE